Drug Delivery for Enhanced Bioavailability of BCS2 (Poorly Soluble) Compounds

Engineered to bring together advanced silica technologies with challenging active pharmaceutical ingredients (APIs) to effectively formulate a large class of poorly soluble but otherwise promising compounds, Grace's SILSOL(R) silica-based drug delivery technology provides solutions for poorly soluble active ingredients. Combining our expertise in mesoporous silica gel, novel application methods, and patented technologies, SILSOL(R) silica can provide solutions for acceleration of the screening and development of solubility enhancing solid dispersions, with the added benefit of doing so with compendial, scalable, and available silicas.